MindImmune Therapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-12-05.
MindImmune Therapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on December 5, 2025. The filing reports $15.22M sold. Its industry group is Pharmaceuticals. It names Isaac Stoner (CEO), Bradley Margus (Director), Christopher O'Donnell (Director) (SEC Form D/A, December 5, 2025).
Sell to companies like MindImmune Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-05 · the record
Pitching, partnering or investing alongside them? See who really runs and owns MindImmune Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind MindImmune Therapeutics, Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when MindImmune Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when MindImmune Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch MindImmune Therapeutics, Inc. →Get the full cited report on MindImmune Therapeutics, Inc.
What the filing shows about MindImmune Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on MindImmune Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for MindImmune Therapeutics, Inc. →
Amended on 2026-03-05: the offering size changed from $12,000,000 to $17,014,485; the amount sold changed from $10,203,858 to $15,218,343; the number of investors changed from 14 to 15. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on MindImmune Therapeutics, Inc. See pricing
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $15.22M, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer, Director.
Isaac Stoner is named as Ceo on the Form D that MindImmune Therapeutics, Inc. filed with the SEC on 5 December 2025, one of 4 people that filing names.
Bradley Margus is named as Director on the Form D that MindImmune Therapeutics, Inc. filed with the SEC on 5 December 2025, one of 4 people that filing names.
Christopher O'Donnell is named as Director on the Form D that MindImmune Therapeutics, Inc. filed with the SEC on 5 December 2025, one of 4 people that filing names.
Reetika Bhardwaj is named as Director on the Form D that MindImmune Therapeutics, Inc. filed with the SEC on 5 December 2025, one of 4 people that filing names.
4 people named on the filing — 1 holding an executive role and 3 as directors only.
Named as of the 2025-12-05 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about MindImmune Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on MindImmune Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MindImmune Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist MindImmune Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind MindImmune Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for MindImmune Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/mindimmune-therapeutics-inc-form-d-25000001